Minerva Neurosciences Inc. (NASDAQ:NERV) fell 2.2% during mid-day trading on Tuesday . The company traded as low as $11.14 and last traded at $11.35, with a volume of 264,334 shares. The stock had previously closed at $11.61.

A number of research firms have issued reports on NERV. Jefferies Group began coverage on shares of Minerva Neurosciences in a report on Thursday, May 12th. They set a “buy” rating and a $10.00 target price on the stock. Zacks Investment Research raised shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Thursday, July 7th. Finally, JMP Securities increased their price objective on shares of Minerva Neurosciences from $10.00 to $17.00 in a research report on Thursday, May 26th.

The company’s 50 day moving average price is $10.52 and its 200 day moving average price is $7.21. The stock’s market cap is $318.26 million.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. On average, analysts anticipate that Minerva Neurosciences Inc. will post ($1.05) earnings per share for the current year.

In related news, Director David Kupfer bought 55,635 shares of the stock in a transaction that occurred on Tuesday, June 21st. The stock was purchased at an average cost of $10.84 per share, for a total transaction of $603,083.40. Following the completion of the acquisition, the director now owns 209,188 shares in the company, valued at $2,267,597.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.